AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio net income
Net income is the profit left for shareholders after every expense, interest and tax.
AnaptysBio's net income for the twelve months ending Jun 30, 2026 was $195.72M. For fiscal 2025 it was -$13.23M. The highest annual figure on record is -$4.26M in fiscal 2016.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.23M | – |
| FY2024 | Dec 31, 2024 | -$145.23M | – |
| FY2023 | Dec 31, 2023 | -$163.62M | – |
| FY2022 | Dec 31, 2022 | -$128.72M | – |
| FY2021 | Dec 31, 2021 | -$57.80M | – |
| FY2020 | Dec 31, 2020 | -$19.93M | – |
| FY2019 | Dec 31, 2019 | -$97.34M | – |
| FY2018 | Dec 31, 2018 | -$61.66M | – |
| FY2017 | Dec 31, 2017 | -$30.07M | – |
| FY2016 | Dec 31, 2016 | -$4.26M | – |
| FY2015 | Dec 31, 2015 | -$5.41M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $183.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$52.88M | – |
| Q4 FY2025 | Dec 31, 2025 | $49.61M | – |
| Q3 FY2025 | Sep 30, 2025 | $15.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.78M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$42.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.85M | – |
| Q1 FY2023 | Mar 31, 2023 | -$44.26M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$33.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$32.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$36.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$32.54M | -196.7% |
| Q3 FY2021 | Sep 30, 2021 | -$6.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$429.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.16M | – |
| Q4 FY2020 | Dec 31, 2020 | $33.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.55M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.26M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.26M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.08M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.09M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.68M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.44M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.58M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.12M | – |
See a number that looks wrong?